Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Aug;2(2):115-52.
doi: 10.1016/j.molonc.2008.04.001. Epub 2008 May 10.

Imaging and cancer: a review

Leonard Fass  1
Affiliations
Review

Imaging and cancer: a review

Leonard Fass. Mol Oncol. 2008 Aug.

Erratum in

Abstract

Multiple biomedical imaging techniques are used in all phases of cancer management. Imaging forms an essential part of cancer clinical protocols and is able to furnish morphological, structural, metabolic and functional information. Integration with other diagnostic tools such as in vitro tissue and fluids analysis assists in clinical decision-making. Hybrid imaging techniques are able to supply complementary information for improved staging and therapy planning. Image guided and targeted minimally invasive therapy has the promise to improve outcome and reduce collateral effects. Early detection of cancer through screening based on imaging is probably the major contributor to a reduction in mortality for certain cancers. Targeted imaging of receptors, gene therapy expression and cancer stem cells are research activities that will translate into clinical use in the next decade. Technological developments will increase imaging speed to match that of physiological processes. Targeted imaging and therapeutic agents will be developed in tandem through close collaboration between academia and biotechnology, information technology and pharmaceutical industries.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Current role of imaging in cancer management.
Figure 2
Figure 2
Future role of imaging in cancer management.
Figure 3
Figure 3
Imaging in the drug discovery process.
Figure 4
Figure 4
Frequency spectrum of electromagnetic radiation imaging technologies.
Figure 5
Figure 5
Relative sensitivity of imaging technologies.
Figure 6
Figure 6
Biomarker imaging.
Figure 7
Figure 7
Advanced lung analysis lesion sizing from 3D CT.
Figure 8
Figure 8
Pre‐ and post‐anti‐angiogenic therapy CT perfusion maps (study courtesy of D. Buthiau, O. Rixe, J. Bloch, J.B. Méric, J.P. Spano, D. Nizri, M. Gatineau, D. Khayat).
Figure 9
Figure 9
MR contrast uptake intensity/time curves in the breast (courtesy of Duke University).
Figure 10
Figure 10
DWI image of metastatic spread (courtesy of the Military Hospital of Laveran, France).
Figure 11
Figure 11
MRI anatomic image and proton spectroscopy of a breast lesion.
Figure 12
Figure 12
Pre‐ and post‐contrast images of a single breast cancer lesion treated by MRgFUS (images courtesy of Breastopia Namba Medical Center, Miyazaki, Japan and InSightec, Haifa, Israel).
Figure 13
Figure 13
Examples of PET tracers in oncology where endogenous substances are framed (courtesy of Imanet Uppsala).
Figure 14
Figure 14
US covered PET indications in oncology.
See this image and copyright information in PMC

References

    1. Aberg, P. , Nicander, I. , Hansson, J. , Geladi, P. , Holmgren, U. , Ollmar, S. , 2004. Skin cancer identification using multifrequency electrical impedance – a potential screening tool. IEEE Transactions on Biomedical Engineering 51, 2097–2102. - PubMed
    1. Aboagye, E.O. , Bhujwalla, Z.M. , 1999. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Research 59, 80–84. - PubMed
    1. Aboagye, E.O. , Bhujwalla, Z.M. , Shungu, D.C. , Glickson, J.D. , 1998. Detection of tumour response to chemotherapy by 1H nuclear magnetic resonance spectroscopy: effect of 5-fluorouracil on lactate levels in radiation-induced fibrosarcoma I tumours. Cancer Research 58, 1063–1067. - PubMed
    1. Abourbeh, G. , Dissoki, S. , Jacobson, O. , 2007. Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors. Nuclear Medicine and Biology 34, 55–70. - PubMed
    1. Albertoni, P. , 2003. Novel antitenascin antibody with increased tumour localisation for pretargeted antibody-guided radioimmunotherapy (PAGRIT). British Journal of Cancer 88, 996–1003. - PMC - PubMed